nodes	percent_of_prediction	percent_of_DWPC	metapath
Arformoterol—CYP2C19—Sorafenib—liver cancer	0.119	0.328	CbGbCtD
Arformoterol—CYP2C9—Sorafenib—liver cancer	0.0992	0.272	CbGbCtD
Arformoterol—CYP2D6—Sorafenib—liver cancer	0.0907	0.249	CbGbCtD
Arformoterol—CYP2D6—Doxorubicin—liver cancer	0.055	0.151	CbGbCtD
Arformoterol—Urethral disorder—Sorafenib—liver cancer	0.00273	0.00594	CcSEcCtD
Arformoterol—Paralysis—Doxorubicin—liver cancer	0.00273	0.00594	CcSEcCtD
Arformoterol—Herpes zoster—Epirubicin—liver cancer	0.00272	0.00593	CcSEcCtD
Arformoterol—Lung disorder—Doxorubicin—liver cancer	0.00268	0.00583	CcSEcCtD
Arformoterol—Hyperlipidaemia—Doxorubicin—liver cancer	0.00263	0.00573	CcSEcCtD
Arformoterol—Abscess—Epirubicin—liver cancer	0.00259	0.00564	CcSEcCtD
Arformoterol—Cardiac disorder—Sorafenib—liver cancer	0.00258	0.00563	CcSEcCtD
Arformoterol—Glycosuria—Epirubicin—liver cancer	0.00253	0.00551	CcSEcCtD
Arformoterol—Herpes zoster—Doxorubicin—liver cancer	0.00252	0.00548	CcSEcCtD
Arformoterol—Immune system disorder—Sorafenib—liver cancer	0.00251	0.00548	CcSEcCtD
Arformoterol—Injection site pain—Epirubicin—liver cancer	0.00251	0.00546	CcSEcCtD
Arformoterol—Mediastinal disorder—Sorafenib—liver cancer	0.00251	0.00546	CcSEcCtD
Arformoterol—Dysphonia—Epirubicin—liver cancer	0.00249	0.00542	CcSEcCtD
Arformoterol—Arrhythmia—Sorafenib—liver cancer	0.00249	0.00542	CcSEcCtD
Arformoterol—Mental disorder—Sorafenib—liver cancer	0.00244	0.00531	CcSEcCtD
Arformoterol—Malnutrition—Sorafenib—liver cancer	0.00242	0.00528	CcSEcCtD
Arformoterol—Abscess—Doxorubicin—liver cancer	0.0024	0.00522	CcSEcCtD
Arformoterol—Dysgeusia—Sorafenib—liver cancer	0.00237	0.00517	CcSEcCtD
Arformoterol—Glycosuria—Doxorubicin—liver cancer	0.00234	0.0051	CcSEcCtD
Arformoterol—Muscle spasms—Sorafenib—liver cancer	0.00233	0.00507	CcSEcCtD
Arformoterol—Injection site pain—Doxorubicin—liver cancer	0.00232	0.00506	CcSEcCtD
Arformoterol—Dysphonia—Doxorubicin—liver cancer	0.0023	0.00502	CcSEcCtD
Arformoterol—Bone disorder—Epirubicin—liver cancer	0.00227	0.00494	CcSEcCtD
Arformoterol—Rectal haemorrhage—Epirubicin—liver cancer	0.00227	0.00494	CcSEcCtD
Arformoterol—Ventricular extrasystoles—Epirubicin—liver cancer	0.00227	0.00494	CcSEcCtD
Arformoterol—Skin discolouration—Epirubicin—liver cancer	0.00227	0.00494	CcSEcCtD
Arformoterol—Viral infection—Epirubicin—liver cancer	0.00227	0.00494	CcSEcCtD
Arformoterol—Herpes simplex—Epirubicin—liver cancer	0.00222	0.00484	CcSEcCtD
Arformoterol—Angioedema—Sorafenib—liver cancer	0.00221	0.00482	CcSEcCtD
Arformoterol—Nocturia—Epirubicin—liver cancer	0.00221	0.00481	CcSEcCtD
Arformoterol—Cough—Sorafenib—liver cancer	0.00212	0.00461	CcSEcCtD
Arformoterol—Atrioventricular block—Epirubicin—liver cancer	0.00211	0.0046	CcSEcCtD
Arformoterol—Inflammation—Epirubicin—liver cancer	0.00211	0.0046	CcSEcCtD
Arformoterol—Skin discolouration—Doxorubicin—liver cancer	0.0021	0.00457	CcSEcCtD
Arformoterol—Rectal haemorrhage—Doxorubicin—liver cancer	0.0021	0.00457	CcSEcCtD
Arformoterol—Bone disorder—Doxorubicin—liver cancer	0.0021	0.00457	CcSEcCtD
Arformoterol—Viral infection—Doxorubicin—liver cancer	0.0021	0.00457	CcSEcCtD
Arformoterol—Ventricular extrasystoles—Doxorubicin—liver cancer	0.0021	0.00457	CcSEcCtD
Arformoterol—Hypertension—Sorafenib—liver cancer	0.00209	0.00456	CcSEcCtD
Arformoterol—Arthralgia—Sorafenib—liver cancer	0.00206	0.00449	CcSEcCtD
Arformoterol—Myalgia—Sorafenib—liver cancer	0.00206	0.00449	CcSEcCtD
Arformoterol—Herpes simplex—Doxorubicin—liver cancer	0.00206	0.00448	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00205	0.00446	CcSEcCtD
Arformoterol—Nocturia—Doxorubicin—liver cancer	0.00204	0.00445	CcSEcCtD
Arformoterol—Dermatitis contact—Epirubicin—liver cancer	0.00203	0.00441	CcSEcCtD
Arformoterol—Dry mouth—Sorafenib—liver cancer	0.00202	0.00439	CcSEcCtD
Arformoterol—Hyperkalaemia—Epirubicin—liver cancer	0.00201	0.00438	CcSEcCtD
Arformoterol—Cystitis noninfective—Epirubicin—liver cancer	0.002	0.00436	CcSEcCtD
Arformoterol—Melaena—Epirubicin—liver cancer	0.002	0.00436	CcSEcCtD
Arformoterol—Cystitis—Epirubicin—liver cancer	0.00198	0.00431	CcSEcCtD
Arformoterol—Anaphylactic shock—Sorafenib—liver cancer	0.00198	0.00431	CcSEcCtD
Arformoterol—Infection—Sorafenib—liver cancer	0.00197	0.00428	CcSEcCtD
Arformoterol—Candida infection—Epirubicin—liver cancer	0.00196	0.00426	CcSEcCtD
Arformoterol—Atrioventricular block—Doxorubicin—liver cancer	0.00195	0.00426	CcSEcCtD
Arformoterol—Inflammation—Doxorubicin—liver cancer	0.00195	0.00426	CcSEcCtD
Arformoterol—Nervous system disorder—Sorafenib—liver cancer	0.00194	0.00422	CcSEcCtD
Arformoterol—Skin disorder—Sorafenib—liver cancer	0.00192	0.00418	CcSEcCtD
Arformoterol—Cramps of lower extremities—Epirubicin—liver cancer	0.00188	0.0041	CcSEcCtD
Arformoterol—Dermatitis contact—Doxorubicin—liver cancer	0.00187	0.00408	CcSEcCtD
Arformoterol—Hyperkalaemia—Doxorubicin—liver cancer	0.00186	0.00406	CcSEcCtD
Arformoterol—Neoplasm—Epirubicin—liver cancer	0.00185	0.00403	CcSEcCtD
Arformoterol—Bladder pain—Epirubicin—liver cancer	0.00185	0.00403	CcSEcCtD
Arformoterol—Cystitis noninfective—Doxorubicin—liver cancer	0.00185	0.00403	CcSEcCtD
Arformoterol—Melaena—Doxorubicin—liver cancer	0.00185	0.00403	CcSEcCtD
Arformoterol—Cystitis—Doxorubicin—liver cancer	0.00183	0.00399	CcSEcCtD
Arformoterol—Candida infection—Doxorubicin—liver cancer	0.00181	0.00394	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Sorafenib—liver cancer	0.0018	0.00392	CcSEcCtD
Arformoterol—Abnormal vision—Epirubicin—liver cancer	0.00179	0.00389	CcSEcCtD
Arformoterol—Dyspnoea—Sorafenib—liver cancer	0.00176	0.00384	CcSEcCtD
Arformoterol—Cramps of lower extremities—Doxorubicin—liver cancer	0.00174	0.00379	CcSEcCtD
Arformoterol—Dyspepsia—Sorafenib—liver cancer	0.00174	0.00379	CcSEcCtD
Arformoterol—Bladder pain—Doxorubicin—liver cancer	0.00171	0.00373	CcSEcCtD
Arformoterol—Neoplasm—Doxorubicin—liver cancer	0.00171	0.00373	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Sorafenib—liver cancer	0.00171	0.00372	CcSEcCtD
Arformoterol—Fatigue—Sorafenib—liver cancer	0.00171	0.00371	CcSEcCtD
Arformoterol—Pain—Sorafenib—liver cancer	0.00169	0.00368	CcSEcCtD
Arformoterol—Constipation—Sorafenib—liver cancer	0.00169	0.00368	CcSEcCtD
Arformoterol—Abnormal vision—Doxorubicin—liver cancer	0.00165	0.0036	CcSEcCtD
Arformoterol—Cardiac failure congestive—Epirubicin—liver cancer	0.00164	0.00357	CcSEcCtD
Arformoterol—Gastrointestinal pain—Sorafenib—liver cancer	0.00162	0.00352	CcSEcCtD
Arformoterol—Urticaria—Sorafenib—liver cancer	0.00157	0.00342	CcSEcCtD
Arformoterol—Body temperature increased—Sorafenib—liver cancer	0.00156	0.0034	CcSEcCtD
Arformoterol—Abdominal pain—Sorafenib—liver cancer	0.00156	0.0034	CcSEcCtD
Arformoterol—Hypoglycaemia—Epirubicin—liver cancer	0.00152	0.00332	CcSEcCtD
Arformoterol—Cardiac failure congestive—Doxorubicin—liver cancer	0.00152	0.0033	CcSEcCtD
Arformoterol—Hypersensitivity—Sorafenib—liver cancer	0.00146	0.00317	CcSEcCtD
Arformoterol—Asthenia—Sorafenib—liver cancer	0.00142	0.00309	CcSEcCtD
Arformoterol—Hypoglycaemia—Doxorubicin—liver cancer	0.00141	0.00307	CcSEcCtD
Arformoterol—Pruritus—Sorafenib—liver cancer	0.0014	0.00305	CcSEcCtD
Arformoterol—Dehydration—Epirubicin—liver cancer	0.00138	0.00301	CcSEcCtD
Arformoterol—Dry skin—Epirubicin—liver cancer	0.00136	0.00297	CcSEcCtD
Arformoterol—Hypokalaemia—Epirubicin—liver cancer	0.00135	0.00295	CcSEcCtD
Arformoterol—Diarrhoea—Sorafenib—liver cancer	0.00135	0.00295	CcSEcCtD
Arformoterol—Nasopharyngitis—Epirubicin—liver cancer	0.00133	0.0029	CcSEcCtD
Arformoterol—Gastritis—Epirubicin—liver cancer	0.00132	0.00287	CcSEcCtD
Arformoterol—Dizziness—Sorafenib—liver cancer	0.00131	0.00285	CcSEcCtD
Arformoterol—Asthma—Epirubicin—liver cancer	0.00129	0.0028	CcSEcCtD
Arformoterol—Influenza—Epirubicin—liver cancer	0.00129	0.0028	CcSEcCtD
Arformoterol—Dehydration—Doxorubicin—liver cancer	0.00128	0.00279	CcSEcCtD
Arformoterol—Dry skin—Doxorubicin—liver cancer	0.00126	0.00275	CcSEcCtD
Arformoterol—Vomiting—Sorafenib—liver cancer	0.00126	0.00274	CcSEcCtD
Arformoterol—Hypokalaemia—Doxorubicin—liver cancer	0.00125	0.00273	CcSEcCtD
Arformoterol—Angina pectoris—Epirubicin—liver cancer	0.00125	0.00273	CcSEcCtD
Arformoterol—Rash—Sorafenib—liver cancer	0.00125	0.00272	CcSEcCtD
Arformoterol—Dermatitis—Sorafenib—liver cancer	0.00125	0.00271	CcSEcCtD
Arformoterol—Headache—Sorafenib—liver cancer	0.00124	0.0027	CcSEcCtD
Arformoterol—Bronchitis—Epirubicin—liver cancer	0.00124	0.00269	CcSEcCtD
Arformoterol—Nasopharyngitis—Doxorubicin—liver cancer	0.00123	0.00268	CcSEcCtD
Arformoterol—Gastritis—Doxorubicin—liver cancer	0.00122	0.00265	CcSEcCtD
Arformoterol—Upper respiratory tract infection—Epirubicin—liver cancer	0.00119	0.0026	CcSEcCtD
Arformoterol—Asthma—Doxorubicin—liver cancer	0.00119	0.00259	CcSEcCtD
Arformoterol—Influenza—Doxorubicin—liver cancer	0.00119	0.00259	CcSEcCtD
Arformoterol—Nausea—Sorafenib—liver cancer	0.00118	0.00256	CcSEcCtD
Arformoterol—Hyperglycaemia—Epirubicin—liver cancer	0.00116	0.00253	CcSEcCtD
Arformoterol—Angina pectoris—Doxorubicin—liver cancer	0.00116	0.00252	CcSEcCtD
Arformoterol—Bronchitis—Doxorubicin—liver cancer	0.00114	0.00249	CcSEcCtD
Arformoterol—Urinary tract infection—Epirubicin—liver cancer	0.00111	0.00243	CcSEcCtD
Arformoterol—Conjunctivitis—Epirubicin—liver cancer	0.00111	0.00243	CcSEcCtD
Arformoterol—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00111	0.00241	CcSEcCtD
Arformoterol—Haematuria—Epirubicin—liver cancer	0.00109	0.00238	CcSEcCtD
Arformoterol—Sinusitis—Epirubicin—liver cancer	0.00108	0.00234	CcSEcCtD
Arformoterol—Hyperglycaemia—Doxorubicin—liver cancer	0.00107	0.00234	CcSEcCtD
Arformoterol—Rhinitis—Epirubicin—liver cancer	0.00103	0.00225	CcSEcCtD
Arformoterol—Conjunctivitis—Doxorubicin—liver cancer	0.00103	0.00224	CcSEcCtD
Arformoterol—Urinary tract infection—Doxorubicin—liver cancer	0.00103	0.00224	CcSEcCtD
Arformoterol—Pharyngitis—Epirubicin—liver cancer	0.00102	0.00222	CcSEcCtD
Arformoterol—Urinary tract disorder—Epirubicin—liver cancer	0.00102	0.00221	CcSEcCtD
Arformoterol—Oedema peripheral—Epirubicin—liver cancer	0.00101	0.00221	CcSEcCtD
Arformoterol—Haematuria—Doxorubicin—liver cancer	0.00101	0.0022	CcSEcCtD
Arformoterol—Connective tissue disorder—Epirubicin—liver cancer	0.00101	0.0022	CcSEcCtD
Arformoterol—Urethral disorder—Epirubicin—liver cancer	0.00101	0.0022	CcSEcCtD
Arformoterol—Sinusitis—Doxorubicin—liver cancer	0.000995	0.00217	CcSEcCtD
Arformoterol—Visual impairment—Epirubicin—liver cancer	0.000992	0.00216	CcSEcCtD
Arformoterol—Cardiac disorder—Epirubicin—liver cancer	0.000955	0.00208	CcSEcCtD
Arformoterol—Rhinitis—Doxorubicin—liver cancer	0.000955	0.00208	CcSEcCtD
Arformoterol—Pharyngitis—Doxorubicin—liver cancer	0.000945	0.00206	CcSEcCtD
Arformoterol—Urinary tract disorder—Doxorubicin—liver cancer	0.00094	0.00205	CcSEcCtD
Arformoterol—Oedema peripheral—Doxorubicin—liver cancer	0.000938	0.00204	CcSEcCtD
Arformoterol—Connective tissue disorder—Doxorubicin—liver cancer	0.000936	0.00204	CcSEcCtD
Arformoterol—Urethral disorder—Doxorubicin—liver cancer	0.000933	0.00203	CcSEcCtD
Arformoterol—Immune system disorder—Epirubicin—liver cancer	0.000929	0.00202	CcSEcCtD
Arformoterol—Mediastinal disorder—Epirubicin—liver cancer	0.000927	0.00202	CcSEcCtD
Arformoterol—Arrhythmia—Epirubicin—liver cancer	0.000919	0.002	CcSEcCtD
Arformoterol—Visual impairment—Doxorubicin—liver cancer	0.000918	0.002	CcSEcCtD
Arformoterol—Mental disorder—Epirubicin—liver cancer	0.000902	0.00196	CcSEcCtD
Arformoterol—Malnutrition—Epirubicin—liver cancer	0.000896	0.00195	CcSEcCtD
Arformoterol—Cardiac disorder—Doxorubicin—liver cancer	0.000884	0.00192	CcSEcCtD
Arformoterol—Tension—Epirubicin—liver cancer	0.000879	0.00191	CcSEcCtD
Arformoterol—Dysgeusia—Epirubicin—liver cancer	0.000877	0.00191	CcSEcCtD
Arformoterol—Nervousness—Epirubicin—liver cancer	0.00087	0.00189	CcSEcCtD
Arformoterol—Back pain—Epirubicin—liver cancer	0.000866	0.00189	CcSEcCtD
Arformoterol—Muscle spasms—Epirubicin—liver cancer	0.000861	0.00188	CcSEcCtD
Arformoterol—Immune system disorder—Doxorubicin—liver cancer	0.00086	0.00187	CcSEcCtD
Arformoterol—Mediastinal disorder—Doxorubicin—liver cancer	0.000858	0.00187	CcSEcCtD
Arformoterol—Arrhythmia—Doxorubicin—liver cancer	0.000851	0.00185	CcSEcCtD
Arformoterol—Mental disorder—Doxorubicin—liver cancer	0.000834	0.00182	CcSEcCtD
Arformoterol—Ill-defined disorder—Epirubicin—liver cancer	0.000831	0.00181	CcSEcCtD
Arformoterol—Malnutrition—Doxorubicin—liver cancer	0.000829	0.0018	CcSEcCtD
Arformoterol—Agitation—Epirubicin—liver cancer	0.000823	0.00179	CcSEcCtD
Arformoterol—Tension—Doxorubicin—liver cancer	0.000813	0.00177	CcSEcCtD
Arformoterol—Dysgeusia—Doxorubicin—liver cancer	0.000812	0.00177	CcSEcCtD
Arformoterol—Malaise—Epirubicin—liver cancer	0.000808	0.00176	CcSEcCtD
Arformoterol—Nervousness—Doxorubicin—liver cancer	0.000805	0.00175	CcSEcCtD
Arformoterol—Back pain—Doxorubicin—liver cancer	0.000802	0.00175	CcSEcCtD
Arformoterol—Muscle spasms—Doxorubicin—liver cancer	0.000797	0.00174	CcSEcCtD
Arformoterol—Palpitations—Epirubicin—liver cancer	0.000792	0.00172	CcSEcCtD
Arformoterol—Cough—Epirubicin—liver cancer	0.000782	0.0017	CcSEcCtD
Arformoterol—Hypertension—Epirubicin—liver cancer	0.000773	0.00168	CcSEcCtD
Arformoterol—Ill-defined disorder—Doxorubicin—liver cancer	0.000769	0.00167	CcSEcCtD
Arformoterol—Arthralgia—Epirubicin—liver cancer	0.000763	0.00166	CcSEcCtD
Arformoterol—Myalgia—Epirubicin—liver cancer	0.000763	0.00166	CcSEcCtD
Arformoterol—Chest pain—Epirubicin—liver cancer	0.000763	0.00166	CcSEcCtD
Arformoterol—Agitation—Doxorubicin—liver cancer	0.000762	0.00166	CcSEcCtD
Arformoterol—Anxiety—Epirubicin—liver cancer	0.00076	0.00165	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000757	0.00165	CcSEcCtD
Arformoterol—Discomfort—Epirubicin—liver cancer	0.000753	0.00164	CcSEcCtD
Arformoterol—Malaise—Doxorubicin—liver cancer	0.000747	0.00163	CcSEcCtD
Arformoterol—Dry mouth—Epirubicin—liver cancer	0.000746	0.00162	CcSEcCtD
Arformoterol—Palpitations—Doxorubicin—liver cancer	0.000732	0.00159	CcSEcCtD
Arformoterol—Oedema—Epirubicin—liver cancer	0.000731	0.00159	CcSEcCtD
Arformoterol—Anaphylactic shock—Epirubicin—liver cancer	0.000731	0.00159	CcSEcCtD
Arformoterol—Infection—Epirubicin—liver cancer	0.000726	0.00158	CcSEcCtD
Arformoterol—Cough—Doxorubicin—liver cancer	0.000723	0.00157	CcSEcCtD
Arformoterol—Nervous system disorder—Epirubicin—liver cancer	0.000717	0.00156	CcSEcCtD
Arformoterol—Hypertension—Doxorubicin—liver cancer	0.000716	0.00156	CcSEcCtD
Arformoterol—Tachycardia—Epirubicin—liver cancer	0.000714	0.00155	CcSEcCtD
Arformoterol—Skin disorder—Epirubicin—liver cancer	0.00071	0.00155	CcSEcCtD
Arformoterol—Arthralgia—Doxorubicin—liver cancer	0.000706	0.00154	CcSEcCtD
Arformoterol—Myalgia—Doxorubicin—liver cancer	0.000706	0.00154	CcSEcCtD
Arformoterol—Chest pain—Doxorubicin—liver cancer	0.000706	0.00154	CcSEcCtD
Arformoterol—Anxiety—Doxorubicin—liver cancer	0.000703	0.00153	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000701	0.00153	CcSEcCtD
Arformoterol—Discomfort—Doxorubicin—liver cancer	0.000697	0.00152	CcSEcCtD
Arformoterol—Dry mouth—Doxorubicin—liver cancer	0.00069	0.0015	CcSEcCtD
Arformoterol—Hypotension—Epirubicin—liver cancer	0.000683	0.00149	CcSEcCtD
Arformoterol—Oedema—Doxorubicin—liver cancer	0.000676	0.00147	CcSEcCtD
Arformoterol—Anaphylactic shock—Doxorubicin—liver cancer	0.000676	0.00147	CcSEcCtD
Arformoterol—Infection—Doxorubicin—liver cancer	0.000672	0.00146	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000666	0.00145	CcSEcCtD
Arformoterol—Nervous system disorder—Doxorubicin—liver cancer	0.000663	0.00144	CcSEcCtD
Arformoterol—Insomnia—Epirubicin—liver cancer	0.000661	0.00144	CcSEcCtD
Arformoterol—Tachycardia—Doxorubicin—liver cancer	0.00066	0.00144	CcSEcCtD
Arformoterol—Skin disorder—Doxorubicin—liver cancer	0.000657	0.00143	CcSEcCtD
Arformoterol—Dyspnoea—Epirubicin—liver cancer	0.000652	0.00142	CcSEcCtD
Arformoterol—Somnolence—Epirubicin—liver cancer	0.00065	0.00142	CcSEcCtD
Arformoterol—Dyspepsia—Epirubicin—liver cancer	0.000644	0.0014	CcSEcCtD
Arformoterol—Hypotension—Doxorubicin—liver cancer	0.000632	0.00138	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Epirubicin—liver cancer	0.000631	0.00137	CcSEcCtD
Arformoterol—Fatigue—Epirubicin—liver cancer	0.00063	0.00137	CcSEcCtD
Arformoterol—Constipation—Epirubicin—liver cancer	0.000625	0.00136	CcSEcCtD
Arformoterol—Pain—Epirubicin—liver cancer	0.000625	0.00136	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000616	0.00134	CcSEcCtD
Arformoterol—Insomnia—Doxorubicin—liver cancer	0.000612	0.00133	CcSEcCtD
Arformoterol—Dyspnoea—Doxorubicin—liver cancer	0.000603	0.00131	CcSEcCtD
Arformoterol—Feeling abnormal—Epirubicin—liver cancer	0.000602	0.00131	CcSEcCtD
Arformoterol—Somnolence—Doxorubicin—liver cancer	0.000601	0.00131	CcSEcCtD
Arformoterol—Gastrointestinal pain—Epirubicin—liver cancer	0.000598	0.0013	CcSEcCtD
Arformoterol—Dyspepsia—Doxorubicin—liver cancer	0.000595	0.0013	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000584	0.00127	CcSEcCtD
Arformoterol—Fatigue—Doxorubicin—liver cancer	0.000583	0.00127	CcSEcCtD
Arformoterol—Urticaria—Epirubicin—liver cancer	0.000581	0.00126	CcSEcCtD
Arformoterol—Pain—Doxorubicin—liver cancer	0.000578	0.00126	CcSEcCtD
Arformoterol—Constipation—Doxorubicin—liver cancer	0.000578	0.00126	CcSEcCtD
Arformoterol—Abdominal pain—Epirubicin—liver cancer	0.000578	0.00126	CcSEcCtD
Arformoterol—Body temperature increased—Epirubicin—liver cancer	0.000578	0.00126	CcSEcCtD
Arformoterol—Feeling abnormal—Doxorubicin—liver cancer	0.000557	0.00121	CcSEcCtD
Arformoterol—Gastrointestinal pain—Doxorubicin—liver cancer	0.000553	0.0012	CcSEcCtD
Arformoterol—Hypersensitivity—Epirubicin—liver cancer	0.000539	0.00117	CcSEcCtD
Arformoterol—Urticaria—Doxorubicin—liver cancer	0.000537	0.00117	CcSEcCtD
Arformoterol—Abdominal pain—Doxorubicin—liver cancer	0.000535	0.00116	CcSEcCtD
Arformoterol—Body temperature increased—Doxorubicin—liver cancer	0.000535	0.00116	CcSEcCtD
Arformoterol—Asthenia—Epirubicin—liver cancer	0.000525	0.00114	CcSEcCtD
Arformoterol—Pruritus—Epirubicin—liver cancer	0.000517	0.00113	CcSEcCtD
Arformoterol—Diarrhoea—Epirubicin—liver cancer	0.0005	0.00109	CcSEcCtD
Arformoterol—Hypersensitivity—Doxorubicin—liver cancer	0.000498	0.00109	CcSEcCtD
Arformoterol—Asthenia—Doxorubicin—liver cancer	0.000485	0.00106	CcSEcCtD
Arformoterol—Dizziness—Epirubicin—liver cancer	0.000483	0.00105	CcSEcCtD
Arformoterol—Pruritus—Doxorubicin—liver cancer	0.000479	0.00104	CcSEcCtD
Arformoterol—Vomiting—Epirubicin—liver cancer	0.000465	0.00101	CcSEcCtD
Arformoterol—Diarrhoea—Doxorubicin—liver cancer	0.000463	0.00101	CcSEcCtD
Arformoterol—Rash—Epirubicin—liver cancer	0.000461	0.001	CcSEcCtD
Arformoterol—Dermatitis—Epirubicin—liver cancer	0.000461	0.001	CcSEcCtD
Arformoterol—Headache—Epirubicin—liver cancer	0.000458	0.000997	CcSEcCtD
Arformoterol—Dizziness—Doxorubicin—liver cancer	0.000447	0.000974	CcSEcCtD
Arformoterol—Nausea—Epirubicin—liver cancer	0.000434	0.000946	CcSEcCtD
Arformoterol—Vomiting—Doxorubicin—liver cancer	0.00043	0.000936	CcSEcCtD
Arformoterol—Rash—Doxorubicin—liver cancer	0.000427	0.000929	CcSEcCtD
Arformoterol—Dermatitis—Doxorubicin—liver cancer	0.000426	0.000928	CcSEcCtD
Arformoterol—Headache—Doxorubicin—liver cancer	0.000424	0.000923	CcSEcCtD
Arformoterol—Nausea—Doxorubicin—liver cancer	0.000402	0.000875	CcSEcCtD
Arformoterol—ADRB1—GPCR downstream signaling—CSF2—liver cancer	0.0001	0.000566	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—CSF2—liver cancer	9.78e-05	0.000554	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—GGT1—liver cancer	9.4e-05	0.000532	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—HPGDS—liver cancer	9.17e-05	0.000519	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—CSF2—liver cancer	9.08e-05	0.000514	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—CSF2—liver cancer	8.88e-05	0.000503	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CPT1B—liver cancer	8.68e-05	0.000491	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GLUL—liver cancer	8.68e-05	0.000491	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—liver cancer	8.57e-05	0.000485	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NR1H4—liver cancer	8.37e-05	0.000474	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ADAM17—liver cancer	8.32e-05	0.000471	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTA3—liver cancer	8.22e-05	0.000466	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PSMD10—liver cancer	8.17e-05	0.000463	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PSMA4—liver cancer	8.17e-05	0.000463	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ADAM17—liver cancer	8.14e-05	0.000461	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CPT1B—liver cancer	7.98e-05	0.000452	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GLUL—liver cancer	7.98e-05	0.000452	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GOT2—liver cancer	7.95e-05	0.00045	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CPT1B—liver cancer	7.91e-05	0.000448	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GLUL—liver cancer	7.91e-05	0.000448	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—F2—liver cancer	7.84e-05	0.000444	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PSMA4—liver cancer	7.82e-05	0.000443	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PSMD10—liver cancer	7.82e-05	0.000443	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NR1H4—liver cancer	7.69e-05	0.000436	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—F2—liver cancer	7.67e-05	0.000434	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PSMA4—liver cancer	7.65e-05	0.000433	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PSMD10—liver cancer	7.65e-05	0.000433	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NR1H4—liver cancer	7.63e-05	0.000432	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTA3—liver cancer	7.56e-05	0.000428	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTA4—liver cancer	7.52e-05	0.000426	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—PIK3CG—liver cancer	7.51e-05	0.000425	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTA3—liver cancer	7.5e-05	0.000425	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CYP2E1—liver cancer	7.48e-05	0.000423	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	7.35e-05	0.000416	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—PIK3CG—liver cancer	7.34e-05	0.000416	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTA2—liver cancer	7.33e-05	0.000415	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—F2—liver cancer	7.12e-05	0.000403	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTA1—liver cancer	7.07e-05	0.0004	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CYCS—liver cancer	6.99e-05	0.000396	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NAT2—liver cancer	6.99e-05	0.000396	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—F2—liver cancer	6.97e-05	0.000394	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTA4—liver cancer	6.92e-05	0.000392	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GOT1—liver cancer	6.86e-05	0.000389	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GGT1—liver cancer	6.86e-05	0.000389	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTA4—liver cancer	6.86e-05	0.000388	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—PIK3CG—liver cancer	6.82e-05	0.000386	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTA2—liver cancer	6.74e-05	0.000382	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—liver cancer	6.72e-05	0.000381	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ALDOB—liver cancer	6.7e-05	0.00038	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	6.7e-05	0.00038	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTA2—liver cancer	6.68e-05	0.000378	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—PIK3CG—liver cancer	6.67e-05	0.000378	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—PIK3CD—liver cancer	6.6e-05	0.000374	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTA1—liver cancer	6.51e-05	0.000368	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—PIK3CD—liver cancer	6.45e-05	0.000365	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTA1—liver cancer	6.45e-05	0.000365	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NAT2—liver cancer	6.43e-05	0.000364	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CRABP1—liver cancer	6.4e-05	0.000362	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NAT2—liver cancer	6.38e-05	0.000361	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ALDOB—liver cancer	6.17e-05	0.000349	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GSTP1—liver cancer	6.16e-05	0.000349	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	6.13e-05	0.000347	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ALDOB—liver cancer	6.11e-05	0.000346	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—HMOX1—liver cancer	6.08e-05	0.000344	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PRKCE—liver cancer	6.06e-05	0.000343	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—PIK3CD—liver cancer	5.99e-05	0.000339	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PRKCE—liver cancer	5.93e-05	0.000336	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CRABP1—liver cancer	5.88e-05	0.000333	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—PIK3CD—liver cancer	5.86e-05	0.000332	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CRABP1—liver cancer	5.83e-05	0.00033	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	5.76e-05	0.000326	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—PIK3CB—liver cancer	5.75e-05	0.000326	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IGF2—liver cancer	5.74e-05	0.000325	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GSTM1—liver cancer	5.67e-05	0.000321	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—PIK3CB—liver cancer	5.63e-05	0.000319	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IGF2—liver cancer	5.62e-05	0.000318	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—HPGDS—liver cancer	5.59e-05	0.000317	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—liver cancer	5.56e-05	0.000315	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CYP1A1—liver cancer	5.37e-05	0.000304	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CSF2—liver cancer	5.36e-05	0.000304	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—RAF1—liver cancer	5.35e-05	0.000303	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—H2AFX—liver cancer	5.28e-05	0.000299	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—IL2—liver cancer	5.28e-05	0.000299	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	5.25e-05	0.000297	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CSF2—liver cancer	5.25e-05	0.000297	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—RAF1—liver cancer	5.23e-05	0.000296	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—PIK3CB—liver cancer	5.22e-05	0.000296	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—H2AFX—liver cancer	5.17e-05	0.000293	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—IL2—liver cancer	5.17e-05	0.000293	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—HPGDS—liver cancer	5.14e-05	0.000291	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—PIK3CB—liver cancer	5.11e-05	0.000289	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—HPGDS—liver cancer	5.1e-05	0.000289	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	5.07e-05	0.000287	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	5.06e-05	0.000287	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—MTHFR—liver cancer	5.01e-05	0.000283	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—liver cancer	5e-05	0.000283	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PSMA4—liver cancer	4.98e-05	0.000282	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PSMD10—liver cancer	4.98e-05	0.000282	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PPARA—liver cancer	4.91e-05	0.000278	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GOT2—liver cancer	4.85e-05	0.000274	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—IL2—liver cancer	4.8e-05	0.000272	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TERT—liver cancer	4.78e-05	0.000271	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—IL2—liver cancer	4.69e-05	0.000266	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TERT—liver cancer	4.67e-05	0.000265	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	4.62e-05	0.000261	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PSMD10—liver cancer	4.58e-05	0.00026	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PSMA4—liver cancer	4.58e-05	0.00026	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP2E1—liver cancer	4.56e-05	0.000258	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	4.56e-05	0.000258	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PSMA4—liver cancer	4.54e-05	0.000257	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PSMD10—liver cancer	4.54e-05	0.000257	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GOT2—liver cancer	4.46e-05	0.000252	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GOT2—liver cancer	4.42e-05	0.00025	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.41e-05	0.00025	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KDR—liver cancer	4.37e-05	0.000247	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MAPK14—liver cancer	4.34e-05	0.000246	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KDR—liver cancer	4.28e-05	0.000242	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYCS—liver cancer	4.26e-05	0.000241	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ESR1—liver cancer	4.26e-05	0.000241	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MAPK14—liver cancer	4.25e-05	0.00024	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—F2—liver cancer	4.21e-05	0.000238	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CG—liver cancer	4.21e-05	0.000238	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP2E1—liver cancer	4.19e-05	0.000237	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GOT1—liver cancer	4.18e-05	0.000237	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GGT1—liver cancer	4.18e-05	0.000237	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ESR1—liver cancer	4.17e-05	0.000236	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP2E1—liver cancer	4.16e-05	0.000235	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—F2—liver cancer	4.12e-05	0.000233	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PPARG—liver cancer	4.06e-05	0.00023	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—APC—liver cancer	4.03e-05	0.000228	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CG—liver cancer	4.03e-05	0.000228	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.02e-05	0.000228	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CG—liver cancer	3.94e-05	0.000223	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—APC—liver cancer	3.94e-05	0.000223	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYCS—liver cancer	3.92e-05	0.000222	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYCS—liver cancer	3.89e-05	0.00022	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GOT1—liver cancer	3.85e-05	0.000218	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GGT1—liver cancer	3.85e-05	0.000218	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GGT1—liver cancer	3.82e-05	0.000216	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GOT1—liver cancer	3.82e-05	0.000216	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—BRAF—liver cancer	3.78e-05	0.000214	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTP1—liver cancer	3.76e-05	0.000213	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—HMOX1—liver cancer	3.71e-05	0.00021	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—BRAF—liver cancer	3.7e-05	0.00021	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CD—liver cancer	3.7e-05	0.000209	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—ALB—liver cancer	3.65e-05	0.000207	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CD—liver cancer	3.54e-05	0.0002	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—PIK3CA—liver cancer	3.51e-05	0.000199	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—SERPINE1—liver cancer	3.5e-05	0.000198	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—KRAS—liver cancer	3.47e-05	0.000196	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CD—liver cancer	3.46e-05	0.000196	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTP1—liver cancer	3.46e-05	0.000196	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTM1—liver cancer	3.45e-05	0.000196	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—PIK3CA—liver cancer	3.43e-05	0.000194	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTP1—liver cancer	3.43e-05	0.000194	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—SERPINE1—liver cancer	3.42e-05	0.000194	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—HMOX1—liver cancer	3.41e-05	0.000193	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—KRAS—liver cancer	3.39e-05	0.000192	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—HMOX1—liver cancer	3.38e-05	0.000191	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP1A1—liver cancer	3.27e-05	0.000185	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CB—liver cancer	3.22e-05	0.000183	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—PIK3CA—liver cancer	3.18e-05	0.00018	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTM1—liver cancer	3.18e-05	0.00018	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—RAF1—liver cancer	3.16e-05	0.000179	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTM1—liver cancer	3.15e-05	0.000178	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—PIK3CA—liver cancer	3.11e-05	0.000176	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—RAF1—liver cancer	3.09e-05	0.000175	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MTOR—liver cancer	3.09e-05	0.000175	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CB—liver cancer	3.09e-05	0.000175	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—MTHFR—liver cancer	3.05e-05	0.000173	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MTOR—liver cancer	3.02e-05	0.000171	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CB—liver cancer	3.02e-05	0.000171	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP1A1—liver cancer	3.01e-05	0.000171	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PPARA—liver cancer	2.99e-05	0.00017	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP1A1—liver cancer	2.99e-05	0.000169	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—HRAS—liver cancer	2.95e-05	0.000167	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CDKN1B—liver cancer	2.9e-05	0.000164	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—HRAS—liver cancer	2.88e-05	0.000163	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—AKT1—liver cancer	2.86e-05	0.000162	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CASP3—liver cancer	2.84e-05	0.000161	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL2—liver cancer	2.83e-05	0.00016	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CDKN1B—liver cancer	2.83e-05	0.00016	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—IL6—liver cancer	2.82e-05	0.00016	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—MTHFR—liver cancer	2.81e-05	0.000159	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—AKT1—liver cancer	2.8e-05	0.000159	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—MTHFR—liver cancer	2.78e-05	0.000158	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CASP3—liver cancer	2.78e-05	0.000157	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL2—liver cancer	2.77e-05	0.000157	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CCND1—liver cancer	2.76e-05	0.000156	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—IL6—liver cancer	2.76e-05	0.000156	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—JUN—liver cancer	2.76e-05	0.000156	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PPARA—liver cancer	2.75e-05	0.000156	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CTNNB1—liver cancer	2.74e-05	0.000155	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PPARA—liver cancer	2.73e-05	0.000155	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CCND1—liver cancer	2.7e-05	0.000153	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—JUN—liver cancer	2.7e-05	0.000153	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.69e-05	0.000152	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MMP9—liver cancer	2.68e-05	0.000152	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CTNNB1—liver cancer	2.68e-05	0.000152	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CDKN1A—liver cancer	2.67e-05	0.000151	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MMP9—liver cancer	2.62e-05	0.000149	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CDKN1A—liver cancer	2.61e-05	0.000148	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MAPK8—liver cancer	2.61e-05	0.000148	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—AKT1—liver cancer	2.6e-05	0.000147	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CG—liver cancer	2.56e-05	0.000145	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MAPK8—liver cancer	2.55e-05	0.000144	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—AKT1—liver cancer	2.54e-05	0.000144	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PPARG—liver cancer	2.48e-05	0.00014	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.45e-05	0.000139	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—VEGFA—liver cancer	2.41e-05	0.000136	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—STAT3—liver cancer	2.38e-05	0.000135	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CG—liver cancer	2.36e-05	0.000134	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—VEGFA—liver cancer	2.36e-05	0.000133	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CG—liver cancer	2.34e-05	0.000132	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—STAT3—liver cancer	2.33e-05	0.000132	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PPARG—liver cancer	2.28e-05	0.000129	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PPARG—liver cancer	2.26e-05	0.000128	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CD—liver cancer	2.25e-05	0.000128	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ALB—liver cancer	2.23e-05	0.000126	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MYC—liver cancer	2.22e-05	0.000125	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TGFB1—liver cancer	2.21e-05	0.000125	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MYC—liver cancer	2.17e-05	0.000123	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TGFB1—liver cancer	2.16e-05	0.000122	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CD—liver cancer	2.07e-05	0.000117	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CD—liver cancer	2.06e-05	0.000116	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KRAS—liver cancer	2.05e-05	0.000116	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ALB—liver cancer	2.05e-05	0.000116	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ALB—liver cancer	2.03e-05	0.000115	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KRAS—liver cancer	2e-05	0.000113	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CB—liver cancer	1.97e-05	0.000111	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CA—liver cancer	1.96e-05	0.000111	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CA—liver cancer	1.88e-05	0.000106	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CA—liver cancer	1.84e-05	0.000104	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TP53—liver cancer	1.82e-05	0.000103	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CB—liver cancer	1.81e-05	0.000102	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CB—liver cancer	1.79e-05	0.000101	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TP53—liver cancer	1.78e-05	0.000101	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HRAS—liver cancer	1.74e-05	9.85e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HRAS—liver cancer	1.7e-05	9.64e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL6—liver cancer	1.67e-05	9.43e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL6—liver cancer	1.63e-05	9.22e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—AKT1—liver cancer	1.61e-05	9.09e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—AKT1—liver cancer	1.54e-05	8.7e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—AKT1—liver cancer	1.5e-05	8.51e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CA—liver cancer	1.2e-05	6.78e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CA—liver cancer	1.1e-05	6.24e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CA—liver cancer	1.09e-05	6.19e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—AKT1—liver cancer	9.79e-06	5.54e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—AKT1—liver cancer	9e-06	5.1e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—AKT1—liver cancer	8.92e-06	5.05e-05	CbGpPWpGaD
